J-P Gregoire
Overview
Explore the profile of J-P Gregoire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodie G, Hagen J, Almamar A, Majumdar S, Wang X, Tuepah R, et al.
Can J Surg
. 2022 Apr;
55(4 Suppl 1):S63-S135.
PMID: 35488395
No abstract available.
2.
Kayibanda J, Girouard C, Gregoire J, Demers E, Moisan J
Res Social Adm Pharm
. 2017 Nov;
14(10):915-920.
PMID: 29089274
Background: The evidence-based heart failure (HF) drug treatment is made of a β-blocker and an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, or hydralazine + isosorbide dinitrate. Little...
3.
Lunghi C, Zongo A, Moisan J, Gregoire J, Guenette L
Diabetes Metab
. 2017 Aug;
43(6):521-528.
PMID: 28822618
Background: Depression has been correlated with suboptimal adherence to antidiabetic drugs (ADs). Most studies on this topic were cross-sectional; thus, the directionality of this relationship could not be established. The...
4.
Guenette L, Zongo A, Guillaumie L, Lauzier S, Blais L, Gregoire J, et al.
Diabetes Metab
. 2017 May;
43(4):368-372.
PMID: 28483291
No abstract available.
5.
Girouard C, Gregoire J, Kayibanda J, Poirier P, Demers E, Moisan J
J Popul Ther Clin Pharmacol
. 2016 Mar;
23(1):e13-25.
PMID: 26949982
Background: Little is known about exposure to heart failure (HF) treatment among seniors with ischemic heart disease. Objectives: In a population of seniors, we: 1) estimated the association between age...
6.
Sirois C, Moisan J, Poirier P, Gregoire J
Int J Clin Pract
. 2014 Nov;
69(3):305-12.
PMID: 25359240
Aims: Although many elderly individuals suffer from type 2 diabetes, the effectiveness of cardioprotective drugs in primary prevention of cardiovascular events in clinical practice in this population has rarely been...
7.
Guenette L, Moisan J, Breton M, Sirois C, Gregoire J
Diabetes Metab
. 2013 Mar;
39(3):250-7.
PMID: 23523643
Aims: This study aimed to assess the 1-year treatment persistence and compliance of new oral antidiabetic drug (OAD) users with their treatment, and to identify the factors associated with both...
8.
Sirois C, Moisan J, Poirier P, Gregoire J
Diabetes Metab
. 2008 Apr;
34(2):169-76.
PMID: 18396087
Aims: To assess whether elderly patients with type 2 diabetes use a comprehensive cardioprotective regimen (CCR) of antihypertensive, lipid-lowering and antiplatelet drugs in the year following oral antidiabetic drug initiation...
9.
Cote I, Moisan J, Chabot I, Gregoire J
J Clin Pharm Ther
. 2005 Jun;
30(4):355-62.
PMID: 15985049
Background And Objective: In a previous study, we observed that a pharmacy-based intervention programme decreased the blood pressure of hypertensive patients. The objective of the present study was to assess...
10.
Bourgault C, Senecal M, Brisson M, Marentette M, Gregoire J
J Hum Hypertens
. 2005 May;
19(8):607-13.
PMID: 15920457
The objective was to assess persistence with antihypertensive therapy (AHT) and discontinuation patterns in patients newly dispensed different antihypertensive drug classes in a natural Canadian population-based setting. Hypertensive patients initiating...